Kiadis Pharma to present at the American Society of Hematology 2019 Annual Meeting
06 Novembre 2019 - 05:50PM
Kiadis Pharma to present at the American Society of Hematology 2019
Annual Meeting
ASH Abstract #
ATIR101: 592, 4464; NK-cell Therapy (K-NK002)
1955
- Phase II data analysis of ATIR101 as an adjunctive treatment
following T-cell depleted haploidentical hematopoietic stem cell
transplantation
- Trial-in-progress overviews of Phase III ATIR101 and Phase II
NK-cell Therapy (K-NK002) clinical trial programs
Amsterdam, The Netherlands, November 6, 2019 – Kiadis Pharma
N.V. (Euronext Amsterdam and Brussels: KDS), a clinical stage
biopharmaceutical company, today announces abstracts showcasing the
potential of the company’s pipeline therapies, (ATIR101 and
K-NK002), will be presented at the 59th Annual Meeting of the
American Society of Hematology (ASH) taking place December 7–10 in
Orlando, Florida.
New ATIR101 data will be discussed in an oral presentation
exploring the effect of a single infusion of ATIR101 on survival
outcomes in patients with blood cancer (including acute myeloid
leukemia [AML], acute lymphoblastic leukemia [ALL], and
myelodysplastic syndromes [MDS]) who underwent T-cell depleted
haploidentical-hematopoietic stem cell transplantation (haplo-HSCT)
from a pooled analysis of two Phase II trials (CR-AIR-007,
NCT01794299; CR-AIR-008, NCT02500550). Additionally, a
trial-in-progress (TIP) overview of the global, randomized ATIR101
Phase III trial (NCT02999854) will be presented, describing the
head-to-head comparison of outcomes of patients who receive ATIR101
after T-cell depleted haplo-HSCT compared to the commonly applied
approach of using post-transplant chemotherapy with
cyclophosphamide (PTCy) in patients who have received a T-cell
replete haplo-HSCT.
Kiadis Pharma will also provide a TIP overview of the
multi-center Phase II trial (BMT CTN 1803) evaluating the efficacy
of K-NK002, Kiadis Pharma’s recently acquired adjunctive
immunotherapeutic, in decreasing risk of relapse in patients with
high-risk AML or MDS undergoing haplo-HSCT.
“Our presence at ASH demonstrates our long-term commitment to
developing personalized, next-generation cell therapies for some of
the hardest to treat blood cancers,” said Arthur Lahr, CEO of
Kiadis Pharma. “By applying highly innovative science in our
clinical programs, we believe our pipeline has potential to bring
us closer to addressing critical unmet needs, not just for
patients, but for the healthcare professionals that treat
them.”
Kiadis Contacts:
Kiadis Pharma: Maryann Cimino, Manager, Corporate Affairs
Tel: +1 (617) 710-7305 m.cimino@kiadis.com
Kiadis Pharma Company Abstracts at ASH 2019
Medicine |
Abstract Number |
Lead Author |
Abstract Title |
Presentation Type |
Presentation time |
ATIR101 |
592 |
Denis Claude Roy |
Addition of ATIR101, an Adjunctive Treatment following
T-Cell-Depleted Haploidentical HSCT, May Decrease Non-relapse
Mortality and May Improve Survival of Patients with Hematologic
Malignancies, Irrespective of Prognostic Risk Factors |
Oral |
Session Name: 711. Cell Collection and Processing Session Date:
Monday, December 9, 2019 Session Time: 7:00 AM - 8:30 AM
Presentation Time: 7:45 AM Room: Orange County Convention Center,
W414AB |
4464 |
Denis Claude Roy |
Head-to-Head Comparison of Haploidentical HSCT Strategies for
Hematologic Malignancies: Phase III HATCY Study of T-Cell-Depleted
HSCT with Adjunctive ATIR101 versus T-Cell-Replete HSCT with
Post‐Transplant Cyclophosphamide |
Poster |
Session Name: 704. Immunotherapies: Poster III Date: Monday,
December 9, 2019 Presentation Time: 6:00 PM - 8:00 PM Location:
Orange County Convention Center, Hall B |
K-NK002 (Previously CSTD002) |
1955 |
Sumithira Vasu |
BMT CTN 1803: Haploidentical Natural Killer Cells (CSTD002) to
Prevent Post-transplant Relapse in AML and MDS (NK-REALM)
|
Poster |
Session Name: 704. Immunotherapies: Poster I
Date: Saturday, December 7, 2019 Presentation
Time: 5:30 PM - 7:30 PM Location: Orange County
Convention Center, Hall B |
About ATIR101 and K-NK002 Administered as adjunctive
immunotherapeutics on top of HSCT, ATIR101 and K-NK002 provide
lymphocyte infusions with functional, mature and potent immune
cells from a haploidentical family member. The T-cells in ATIR101
and NK-cells in K-NK002 will help fight infections and remaining
tumor cells, until the immune system has fully re-grown from stem
cells in the transplanted graft. In addition, K-NK002 has shown
promise in the treatment of relapse/refractory AML.
In ATIR101, T-cells that would cause GVHD are depleted from the
donor lymphocytes, using our photodepletion technology. At the same
time, ATIR101 contains potential cancer-killing T-cells from the
donor that could eliminate residual cancer cells and help prevent
relapse of the disease. Furthermore, the donor lymphocytes retain
their immune function and help protect the patient from
infection.
In K-NK002, nanoparticle processing technology enables improved
ex vivo expansion and activation of NK-cells supporting multiple
high-dose infusions with potent anti-cancer cytotoxicity.
About KiadisFounded in 1997, Kiadis Pharma, is a fully
integrated biopharmaceutical company committed to developing
innovative therapies for patients with life threatening diseases.
With headquarters in Amsterdam, the Netherlands, and offices in the
US and across Europe, Kiadis Pharma is leveraging the natural
strengths of humanity and our collective immune system to source
the best cells for life.
Kiadis Pharma is listed on the regulated market of Euronext
Amsterdam and Euronext Brussels since July 2, 2015, under the
symbol KDS. Learn more at www.kiadis.com.
Forward Looking Statements Certain statements,
beliefs and opinions in this press release are forward-looking,
which reflect Kiadis Pharma’s or, as appropriate, Kiadis Pharma’s
directors’ current expectations and projections about future
events. By their nature, forward-looking statements involve a
number of risks, uncertainties and assumptions that could cause
actual results or events to differ materially from those expressed
or implied by the forward-looking statements. These risks,
uncertainties and assumptions could adversely affect the outcome
and financial effects of the plans and events described herein. A
multitude of factors including, but not limited to, changes in
demand, regulation, competition and technology, can cause actual
events, performance or results to differ significantly from any
anticipated development. Forward-looking statements contained in
this press release regarding past trends or activities should not
be taken as a representation that such trends or activities will
continue in the future. As a result, Kiadis Pharma expressly
disclaims any obligation or undertaking to release any update or
revisions to any forward-looking statements in this press release
as a result of any change in expectations or any change in events,
conditions, assumptions or circumstances on which these
forward-looking statements are based. Neither Kiadis Pharma nor its
advisers or representatives nor any of its subsidiary undertakings
or any such person’s officers or employees guarantees that the
assumptions underlying such forward-looking statements are free
from errors nor does either accept any responsibility for the
future accuracy of the forward-looking statements contained in this
press release or the actual occurrence of the forecasted
developments. You should not place undue reliance on
forward-looking statements, which speak only as of the date of this
press release.